BioSpace News Archive

Akoya Biosciences to Present at the 39 th Annual J.P. Morgan Healthcare Conference on January 13, 2021

- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today issued a Letter to Shareholders from Spiros Jamas, Sc.D, its newly appointed Chief Executive Officer and a member of its Board of Directors.

- Preliminary Full-Year 2020 Net Product Sales for CINV Franchise of Approximately $88.3 Million, versus Guidance of $85 Million - - Full-Year 2021 Net Product Sales Guidance for CINV Franchise of $130 Million to $145 Million - - New Drug Application for HTX-011 for Postoperative Pain Management is Under Review in the US with a May 12, 2021 PDUFA Date - - Preliminary Results From Phase 1b Bunionectomy Study with HTX-034 Shows Pain Reduction Through 96 Hours with 45.

Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guidance. Cerus’ unaudited preliminary product revenue for the fourth quarter of 2020 totaled $28.2 million, an increase of 35% over the $20.9 million recognized during the same period in the prior year.

ProTom International Holding Corporation is pleased to announce that it has signed a distribution and licensing agreement with Guohong Guokang Health Technology Development Co., LTD who, along with its affiliates, is one of the leading comprehensive high-tech innovative enterprises in China for an exclusive distribution and licensing Agreement to distribute ProTom’s Radiance 330® Proton Therapy System in mainland China.

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the U.S. Food and Drug Administration (FDA) has granted ReNu®,

Noctrix Health, Inc., a private medical device company, today announced it has completed a Series B financing of $17 million . The financing was co-led by Treo Ventures and OrbiMed, with participation from LivaNova PLC (NASDAQ: LIVN) and other insiders.

HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today that it has received approval to initiate the company’s second European clinical trial of its new platform technology

Multiyear partnership brings together advanced technology, industry expertise and scale to help researchers interpret an unprecedented amount of biomedical data and derive insights to advance the treatment of human diseases

Broome Oncology LLC and Deep Lens announced today that the two companies are collaborating on an initiative to rapidly and effectively match patients to precision therapies and clinical studies with Deep Lens’ artificial intelligence-based screening and enrollment platform, called VIPER™. With the upcoming integration of VIPER to Broome Oncology, clinical trial care team members will improve the